Positron Emission Tomography Neuro-Imaging
DOI:
https://doi.org/10.17140/NOJ-1-102Keywords:
Radiotracer; Positron Emission Tomography (PET); Neurology; Alzheimer’s disease; Parkinson’s disease; Epilepsy; Multiple sclerosis.Abstract
Positron Emission Tomography (PET) is a powerful imaging technique exploring in
vivo brain functions. Today PET is becoming an essential tool in specialist clinical neurology
settings particularly for diagnosing Alzheimer’s, Parkinson’s and epilepsy disease states. This
inaugural article aims to deliver a brief insight in
References
Rontgen and the discovery of X-rays. Br J Radiol. 1995; 68(815): 1145-1176.
Flower MA. Webb’s physics of medical imaging. CRC Press, 2012.
Cherry SR. The 2006 Henry N. Wagner lecture: of mice and men (and positrons) - advances in PET imaging technology. J Nucl Med. 2006; 47(11): 1735-1745.
Kitson SL, Cuccurullo V, Ciarmiello A, Salvo D, Mansi, L. Clinical applications of positron emission tomography (PET) imaging in medicine: oncology, brain diseases and cardiology. Curr Radiopharm. 2009; 2: 224-253.
Roß TL, Ametamey SM. PET chemistry: radiopharmaceu-ticals. In: Basic sciences of nuclear medicine. Springer Berlin Heidelberg. 2011; 103-118.
Cherry SR. Fundamentals of positron emission tomography andapplicationsinpreclinicaldrugdevelopment.JClinPharma-col. 2001; 41(5): 482-491. doi: 10.1177/00912700122010357
Nutt R. The history of positron emission tomography. Mol Imaging Biol. 2002; 1(4): 11-26. doi: 10.1016/S1095-0397- (00)00051-0
Brownell GL. A history of positron imaging. Website: http:// neurosurgery.mgh.harvard.edu/docs/PEThistory.pdf 1999; Ac-cessed March 15, 2014.
Hung JC, Callanhan RJ. USP and PET radiopharmaceuticals: 1997 FDAMA puts standard-setting body at center of regula-tory process. J Nucl Med. 2004; 45(1): 13N-14N, 16N.
Klabbers BM, Lammertsma AA, Slotman BJ. The value of positron emission tomography for monitoring response to ra-diotherapy in head-and-neck cancer. Mol Imaging Biol. 2003; 4(5): 257-270.
Coleman RE, Hoffman JM, Hanson MW, Sostman HD, Schold SC. Clinical application of PET for the evaluation of brain tumors. J Nucl Med. 1991; 32(4): 616-622.
Lee C-M, Farde L. Using positron emission tomogra-phy to facilitate CNS drug development. Trends Pharmacol Sci. 2006; 27(6): 310-316. doi: http://dx.doi.org/10.1016/j. tips.2006.04.004
Jain M, Batra SK. Genetically engineered antibody frag-ments and PET imaging: A new era of radioimmunodiagnosis. J Nucl Med. 2003; 44(12): 1970-1972.
Beeres SLMA, Bengel FM, Bartunek J, et al. Role of im-aging in cardiac stem cell therapy. J Am Coll Cardiol. 2007; 49(11): 1137-1148. doi: 10.1016/j.jacc.2006.10.072
von Schulthess GK. Positron emission tomography versus positron emission tomography/computed tomography: From ‘Unclear’ to ‘New-Clear’ medicine. Mol Imaging Biol. 2004; 6(4): 183-187.
Surti S, Karp JS. Imaging characteristics of a 3-dimension-al GSO whole-body PET camera. J Nucl Med. 2004; 45(6): 1040-1049.
Alavi A, Lakhani P, Mavi A, Kung JW, Zhuang H. PET: a revolution in medical imaging. Radiol Clin of N Am. 2004; 42(6): 983-1001.
Herholz K, Heiss W-D. Positron emission tomography in clinical neurology. Mol Imaging Biol. 2004; 6(4): 239-269.
Jones T, Rabiner EA. The development, past achievements, and future directions of brain PET. J Cereb Blood Flow Metab. 2012; 32(7): 1426-1454. doi: 10.1038/jcbfm.2012.20
Venneri A. Imaging treatment effects in Alzheimer’s dis-ease. Magn Reson Imaging. 2007; 25(6): 953-968. doi: http:// dx.doi.org/10.1016/j.mri.2007.02.004
Silverman DHS, Cummings JL, Small GW, et al. Added clinical benefit of incorporating 2-Deoxy-2-[18F]Fluoro-D-Glucose with positron emission tomography into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol. 2002; 4(4): 283-293.
Nordberg A. PET imaging of amyloid in Alzheimer’s dis-ease. Lancet Neurol. 2004; 3(9): 519-527. doi: http://dx.doi. org/10.1016/S1474-4422(04)00853-1
Kitson SL. 5-Hydroxytyptamine (5-HT) receptor ligands. Curr Pharma Design. 2007; 13(25): 2621-2637. doi: 10.2174/ 138161207781663000#sthash.AYCWvomF.dpuf
Klunk WE, Engler H, Nordberg A. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann of Neurol. 2004; 55(3): 306-319. doi: 10.1002/ana.20009
U.S. Food and Drug Administration Press Release. FDA approves second brain imaging drug to help evaluate patients for Alzheimer’s disease, dementia, 2013. http://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm372261.htm; Accessed 2014.
U.S. Food and Drug Administration Press Release. FDA approves imaging drug Amyvid, 2012. http://www.fda.gov/ newsevents/newsroom/pressannouncements/ucm299678.htm; Accessed 2014.
Björklund A, Dunnett SB. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007; 30(5): 194-202. doi:
Ravina B, Eidelberg D, Ahlskog JE. et al. The role of ra-diotracer imaging in Parkinson disease. Neurology. 2005; 64(2): 208-215.
Cliffe IA. A retrospect on the discovery of WAY-1000635 and the prospect for improved 5-HT1A receptor PET radioli-gands. Nucl Med Biol. 2000; 27(5): 441-447.
Kang KW, Lee DS, Cho JH, et al. Quantification of F-18 FDG PET images in temporal lobe epilepsy patients using probabilistic brain atlas. Neuroimage. 2001; 14(1 Pt 1): 1-6. doi: 10.1006/nimg.2001.0783
Bouvard S, Costes F, Bonnefoi F, et al. Seizure-related short-term plasticity of benzodiazepine receptors in parial epi-lepsy: a [11C]flumazenil - PET study. Brain. 2005; 128(Pt 6): 1330-1343. doi: http://dx.doi.org/10.1093/brain/awh470
Chunying Wu, Changing W, Daniela P, et al. A nov-el PET marker for in vivo quantification of myelination. Bioorg Med Chem. 2010; 18(24): 8592-8599. doi: 10.1016/j. bmc.2010.10.018
Schroeter M, Dennin MA, Walberer M, et al. Neuroinflam-mation extends brain tissue at risk to vital peri-infarct tissue: a double tracer [11C]PK11195- and [18F]FDG-PET study. J Cereb Blood Flow Metab. 2009; 29(6): 1216-1225. doi: 10.1038/jcbfm.2009.36
Riley C, Azevedo C, Bailey M, Pelletier. Clinical applica-tions of imaging disease burden in multiple sclerosis. Expert Rev Neurother. 2012; 12(3): 323-333. doi: 10.1586/ern.11.196
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Neuro (NEURO) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.